中晚期鼻咽癌中核苷酸切除修复交叉互补基因1表达与铂类药物疗效的相关性研究

李文华; 孙奇; 陆妹英

doi:10.13201/j.issn.1001-1781.2015.02.013

中晚期鼻咽癌中核苷酸切除修复交叉互补基因1表达与铂类药物疗效的相关性研究

- 柳州市工人医院病理科(广西柳州, 545005)

详细信息

通讯作者: 李文华,E-mail:liwenhua206@qq.com

中图分类号: R739.63

收稿日期: 2014-07-23

Correlation between expression of ERCC1 and the treatment of cisplatinbased chemotherapy in local advanced nasopharyngeal carcinoma

- Department of Pathology, Liuzhou Worker's Hospital, Liuzhou, 545005, China

More Information

Corresponding author: LI Wenhua, E-mail: liwenhua206@qq.com

Received Date: 23 July 2014

摘要

摘要: 目的:探讨中晚期鼻咽癌组织中核苷酸切除修复交叉互补基因1(ERCC1)的表达,并分析其表达与铂类药物化疗疗效的关系。方法:采用免疫组织化学方法检测107例中晚期鼻咽癌组织及48例癌旁组织中的ERCC1的表达情况。结果:ERCC1在鼻咽癌组织中低表达55例,高表达52例,而癌旁组织中低表达30例,高表达18例,2组差异无统计学意义。ERCC1表达与鼻咽癌患者临床综合分期有关,与年龄、性别、组织学类型、T分期、N分期均无关。ERCC1低表达病例近期治疗有效率(81.8%)比高表达病例近期有效率(63.5%)高,二者差异有统计学意义。97例随访,2例发生死亡,5例发生肝或肺转移,ERCC1不同组间的差异无统计学意义。结论:ERCC1蛋白可作为预测鼻咽癌患者对铂类药物化疗敏感性的指标之一,也有助于肿瘤患者个体化治疗方案制定,而免疫组织化学检测亦是简便而有效的检测手段,值得广泛推广。
- 核苷酸切除修复交叉互补基因1 /
- 鼻咽癌 /
- 化疗 /
- 免疫组织化学
Abstract: Objective: To study the expression of excision repair cross-complementing 1(ERCC1) and the treatment of cisplatin-based chemotherapy in local advanced nasopharyngeal carcinoma (NPC). Method: The expression of ERCC1 protein in 107 cases with NPC and in 48 normal nasopharyngeal tissues adjacent to the cancer was detected by immunohistochemical method. Result: High expression of ERCC1 was observed in 52 cases with NPC, and 18 cases normal nasopharyngeal tissues, there was no statistically significant differences between them. The expression of ERCC1 protein was significant correlated with patient total TNM stage, but not significantly correlated with age, gender, histological type, T stage and N stage. The recent treatment efficiency in Low ERCC1 expression cases was higher than high expression cases. There was statistically significant difference between them. In 97 follow-up cases, 2 cases died, 5 cases with liver and lung metastasis, there was no statistically significant difference between them.Conclusion: ERCC1 expression maybe regarded as indicator platinum based chemotherapy sensitivity prediction in nasopharyngeal carcinoma, and also helpful for formulating individualized treatment. The immunohistochemical detection is also simple and effective detection method for ERCC1 expression.
- excision repair cross-complementing 1 /
- nasopharyngeal carcinoma /
- chemotherapy /
- immunohistochemical

HTML全文

参考文献(12)

[1]	AL-SARRAF M, LEBLANC M, GIRI P G, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer:phase Ⅲ randomized intergroup study 0099[J]. J Clin Oncol,1998,16:1310-1317.
[2]	LEE A W, SZE W M, AU J S, et al. Treatment results for nasopharyngeal carcinoma in the modern era:the Hong Kong experience[J]. Int J Radiat Oncol Biol Phys, 2005,61:1107-1116.
[3]	HWANG I G, AHN M J, PARK B B, et al. ERCC1 expression as a prognostic marker in N2(+) non small-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy[J]. Cancer, 2008,113:1379-1386.
[4]	ARORA S, KOTHANDAPANI A, TILLISON K, et al. Down regulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells[J]. DNA Repair(Amst),2010,9:745-753.
[5]	REED E.ERCC1 and clinical resistance to platinum-based therapy[J].Clin Cancer Res,2005,11:6100-6102.
[6]	AHMAD A, ROBINSON A R, DUENSING A, et al. ERCC1-XPF endonu-clease facilitates DNA double strand break repair[J]. Mol Cell Biol, 2008, 28:5082-5092.
[7]	曹秩林, 刘陶文, 邱小芬, 等. 鼻咽癌组织ERCC1的表达及其临床意义[J]. 中华肿瘤防治杂志, 2010, 17(2):105-107.
[8]	李工, 薛晓光, 欧阳翼, 等. ERCC1、hMLH1表达对局部中晚期鼻咽癌调强放疗的影响[J].广东医学, 2012, 33(23):3549-3552.
[9]	CHAN S H, CHEUNG F M, NG W T, et al. Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2011,79:1414-1420.
[10]	SUN J M, AHN M J, PARK M J, et al. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy[J]. Int J Radiat Oncol Biol Phys,2011,80:655-660.
[11]	HUANG P Y, LI Y,MAI H Q, et al. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy[J]. Oral Oncol,2012,48:964-968.
[12]	LEE H W,HWANG Y H,HAN J H,et al. High expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with nasopharyngeal cancer[J]. Oral Oncol,2010, 46:209-213.